Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor–Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
Marco Colleoni(European Institute of Oncology), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Daniel Rauch(Washington University in St. Louis), Fabio Puglisi(University of Udine), Meredith M. Regan(Dana-Farber Cancer Institute), Elena Kralidis(Ospedale San Giuseppe), Richard D. Gelber(Harvard University), Carlo Tondini(Ospedale Papa Giovanni XXIII), Henry Gómez(National Cancer Center), Shari Gelber(Frontier Science & Technology Research Foundation), Kathryn P. Gray(Dana-Farber Cancer Institute), Barbro Linderholm(Karolinska University Hospital), Alexandru Eniu(Institute of Oncology Prof. Dr. Ion Chiricuta), Beat Thürlimann(University of St.Gallen), Alan S. Coates(International Breast Cancer Study Group), Jacquie Chirgwin(Uppsala University Hospital), Ehtesham Abdi, Giuseppe Viale(University of Milan), Karen N. Price(International Breast Cancer Study Group), István Láng(Roche (Switzerland)), Lorenzo Gianni
Cited by 77
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k